8-K Announcements
6Material company update
Apr 15, 2026·SEC
Material company update
Mar 5, 2026·SEC
Material company update
Jan 8, 2026·SEC
Tango Therapeutics, Inc.(TNGX)Earnings, Financials & Key Ratios
TNGX•NASDAQ
$23.62
$3.21B mkt cap·Price updated May 6, 2026
AboutTango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.Show more
- Revenue$62M+48.3%
- EBITDA-$109M+23.8%
- Net Income-$102M+22.0%
- EPS (Diluted)-0.87+26.9%
- Gross Margin96.34%-3.7%
- EBITDA Margin-174.74%+48.6%
- Operating Margin-178.39%+48.5%
- Net Margin-162.85%+47.4%
- ROE-37.23%+35.3%
- ROIC-38.47%+30.9%
- Debt/Equity0.10-47.0%
TNGX Key Insights
Tango Therapeutics, Inc. (TNGX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 97 (top 3%)
- ✓High quality earnings: Operating CF exceeds net income
- ✓Strong 5Y sales CAGR of 52.1%
✗Weaknesses
- ✗Negative free cash flow
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
TNGX Price & Volume
Tango Therapeutics, Inc. (TNGX) stock price & volume — 10-year historical chart
Loading chart...
TNGX Growth Metrics
Tango Therapeutics, Inc. (TNGX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years52.13%
3 Years35.89%
TTM48.29%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM22.03%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM27.5%
Return on Capital
10 Years-37.1%
5 Years-31.16%
3 Years-36.93%
Last Year-33.96%
TNGX Recent Earnings
Tango Therapeutics, Inc. (TNGX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 5/12 qtrs (45%)
Q2 2026Latest
Mar 5, 2026EPS
$0.29
Est $0.31
+6.5%
Revenue
—
Est $500,400
Q4 2025
Nov 4, 2025EPS
$0.13
Est $0.01
+1200.0%
Revenue
$54M
Est $556,000
+9578.2%
Q3 2025
Aug 5, 2025EPS
$0.35
Est $0.35
+0.0%
Revenue
$3M
Est $6M
-50.3%
Q2 2025
May 12, 2025EPS
$0.36
Est $0.34
-5.9%
Revenue
$5M
Est $6M
-15.2%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 5, 2026 | $0.29vs $0.31+6.5% | —vs $500,400 |
| Q4 2025 | Nov 4, 2025 | $0.13vs $0.01+1200.0% | $54Mvs $556,000+9578.2% |
| Q3 2025 | Aug 5, 2025 | $0.35vs $0.35+0.0% | $3Mvs $6M-50.3% |
| Q2 2025 | May 12, 2025 | $0.36vs $0.34-5.9% | $5Mvs $6M-15.2% |
Based on last 12 quarters of dataView full earnings history →
TNGX Peer Comparison
Tango Therapeutics, Inc. (TNGX) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RVMD | 32.12B | 151.07 | -25.39 | -83.22% | 0.10 | |||
 KYMR | 7.04B | 86.26 | -23.38 | -16.72% | -6.12% | -25.02% | 0.05 | |
 PRAX | 7.61B | 337.95 | -25.07 | -100% | -58.74% | 0.00 | ||
 AUPH | 2.15B | 16.25 | 7.85 | 20.38% | 101.47% | 49.4% | 0.13 | |
 PMVP | 76.84M | 1.45 | -1.27 | -55.34% | 0.01 | |||
 ARQT | 3.02B | 24.17 | -185.92 | 91.34% | -0.57% | -1.41% | 0.03 | |
 NUVL | 6.92B | 104.26 | -26.53 | -45.12% | ||||
 TYRA | 1.82B | 33.80 | -16.82 | -41.17% | 0.02 |
Compare TNGX vs Peers
Tango Therapeutics, Inc. (TNGX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TNGX Income Statement
Tango Therapeutics, Inc. (TNGX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 24.65M | 7.66M | 37.04M | 24.86M | 36.53M | 42.07M | 62.38M |
| Revenue Growth % | - | -68.94% | 383.83% | -32.89% | 46.93% | 15.17% | 48.29% |
| Cost of Goods Sold | 32.27M | 1.63M | 0 | 0 | 0 | 0 | 2.28M |
| COGS % of Revenue | 130.93% | 21.23% | - | - | - | - | 3.66% |
| Gross Profit | -7.63M▲ 0% | 6.03M▲ 179.1% | 37.04M▲ 514.2% | 24.86M▼ 32.9% | 36.53M▲ 46.9% | 42.07M▲ 15.2% | 60.1M▲ 42.9% |
| Gross Margin % | -30.93% | 78.77% | 100% | 100% | 100% | 100% | 96.34% |
| Gross Profit Growth % | - | 179.1% | 514.19% | -32.89% | 46.93% | 15.17% | 42.87% |
| Operating Expenses | 7.54M | 58.23M | 95.23M | 135.93M | 150.7M | 187.66M | 171.39M |
| OpEx % of Revenue | 30.58% | 760.59% | 257.09% | 546.79% | 412.57% | 446.09% | 274.74% |
| Selling, General & Admin | 7.54M | 8.24M | 17.6M | 30.02M | 35.5M | 43.75M | 41.51M |
| SG&A % of Revenue | 30.58% | 107.63% | 47.5% | 120.78% | 97.19% | 103.99% | 66.54% |
| Research & Development | 32.27M | 49.99M | 77.64M | 105.91M | 115.2M | 143.92M | 132.16M |
| R&D % of Revenue | 130.93% | 652.97% | 209.59% | 426.01% | 315.38% | 342.1% | 211.86% |
| Other Operating Expenses | -32.27M | 0 | 0 | 0 | 0 | 0 | -2.28M |
| Operating Income | -15.16M▲ 0% | -52.2M▼ 244.3% | -58.19M▼ 11.5% | -111.07M▼ 90.9% | -114.17M▼ 2.8% | -145.59M▼ 27.5% | -111.29M▲ 23.6% |
| Operating Margin % | -61.51% | -681.82% | -157.09% | -446.79% | -312.57% | -346.09% | -178.39% |
| Operating Income Growth % | - | -244.28% | -11.48% | -90.88% | -2.79% | -27.52% | 23.56% |
| EBITDA | -14.52M | -50.58M | -57.29M | -109.46M | -111.76M | -143.1M | -109.01M |
| EBITDA Margin % | -58.9% | -660.59% | -154.67% | -440.32% | -305.96% | -340.15% | -174.74% |
| EBITDA Growth % | - | -248.34% | -13.28% | -91.06% | -2.1% | -28.04% | 23.82% |
| D&A (Non-Cash Add-back) | 643K | 1.63M | 897K | 1.61M | 2.42M | 2.5M | 2.28M |
| EBIT | -15.16M | -51.97M | -58.19M | -111.07M | -114.17M | -145.59M | -111.29M |
| Net Interest Income | 684K | 108K | 495K | 1.46M | 6.62M | 7.89M | 5.63M |
| Interest Income | 684K | 108K | 495K | 1.46M | 6.62M | 7.89M | 5.63M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 1.07M | 228K | 247K | 2.95M | 12.56M | 15.5M | 9.7M |
| Pretax Income | -14.1M▲ 0% | -51.97M▼ 268.7% | -57.94M▼ 11.5% | -108.12M▼ 86.6% | -101.61M▲ 6.0% | -130.09M▼ 28.0% | -101.59M▲ 21.9% |
| Pretax Margin % | -57.18% | -678.84% | -156.43% | -434.92% | -278.18% | -309.24% | -162.85% |
| Income Tax | 0 | 0 | 292K | 54K | 134K | 208K | 4K |
| Effective Tax Rate % | 0% | 0% | -0.5% | -0.05% | -0.13% | -0.16% | -0% |
| Net Income | -14.1M▲ 0% | -51.97M▼ 268.7% | -58.23M▼ 12.1% | -108.18M▼ 85.8% | -101.74M▲ 5.9% | -130.3M▼ 28.1% | -101.59M▲ 22.0% |
| Net Margin % | -57.18% | -678.84% | -157.21% | -435.14% | -278.54% | -309.73% | -162.85% |
| Net Income Growth % | - | -268.73% | -12.05% | -85.76% | 5.95% | -28.07% | 22.03% |
| Net Income (Continuing) | -14.1M | -51.97M | -58.23M | -108.18M | -101.74M | -130.3M | -101.59M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.57▲ 0% | -1.62▼ 3.2% | -0.94▲ 42.0% | -1.23▼ 30.9% | -1.08▲ 12.2% | -1.19▼ 10.2% | -0.87▲ 26.9% |
| EPS Growth % | - | -3.18% | 41.98% | -30.85% | 12.2% | -10.19% | 26.89% |
| EPS (Basic) | -1.57 | -1.62 | -0.94 | -1.23 | -1.08 | -1.19 | -0.87 |
| Diluted Shares Outstanding | 87.47M | 87.47M | 62.11M | 87.82M | 94.57M | 109.23M | 116.17M |
| Basic Shares Outstanding | 87.47M | 87.47M | 62.11M | 87.82M | 94.57M | 109.23M | 116.17M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
TNGX Balance Sheet
Tango Therapeutics, Inc. (TNGX) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 41.66M | 193.63M | 492.34M | 375.27M | 346.54M | 266.34M | 353.76M |
| Cash & Short-Term Investments | 40.42M | 190.32M | 485.25M | 366.13M | 336.88M | 257.92M | 343.14M |
| Cash Only | 22.89M | 28.38M | 142.75M | 59.97M | 66.39M | 69.53M | 112.28M |
| Short-Term Investments | 17.54M | 161.94M | 342.51M | 306.17M | 270.5M | 188.39M | 230.86M |
| Accounts Receivable | 0 | 2M | 2M | 2M | 0 | 0 | 0 |
| Days Sales Outstanding | - | 95.35 | 19.71 | 29.36 | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 567K | 7.14M | 9.65M | 8.43M | 10.62M |
| Total Non-Current Assets | 14.11M | 13.62M | 7.82M | 61.2M | 56.03M | 50.15M | 44.93M |
| Property, Plant & Equipment | 11.83M | 11.3M | 6.09M | 57.77M | 53.42M | 47.58M | 42.49M |
| Fixed Asset Turnover | 2.08x | 0.68x | 6.09x | 0.43x | 0.68x | 0.88x | 1.47x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 2.28M | 2.32M | 1.73M | 3.43M | 2.61M | 2.57M | 2.44M |
| Total Assets | 55.76M▲ 0% | 207.25M▲ 271.7% | 500.15M▲ 141.3% | 436.47M▼ 12.7% | 402.57M▼ 7.8% | 316.49M▼ 21.4% | 398.69M▲ 26.0% |
| Asset Turnover | 0.44x | 0.04x | 0.07x | 0.06x | 0.09x | 0.13x | 0.16x |
| Asset Growth % | - | 271.66% | 141.33% | -12.73% | -7.77% | -21.38% | 25.97% |
| Total Current Liabilities | 25.85M | 40.92M | 40.69M | 55.55M | 45.94M | 38.17M | 21.68M |
| Accounts Payable | 670K | 1.84M | 3.23M | 4.45M | 2.79M | 1.6M | 1.18M |
| Days Payables Outstanding | 7.58 | 413.52 | - | - | - | - | 189.14 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 2.74M |
| Deferred Revenue (Current) | 0 | 31.98M | 26.02M | 31.79M | 25.67M | 17.62M | 0 |
| Other Current Liabilities | 19.93M | 793K | 666K | 1.27M | 7.49M | 1.74M | 17.76M |
| Current Ratio | 1.61x | 4.73x | 12.10x | 6.76x | 7.54x | 6.98x | 16.32x |
| Quick Ratio | 1.61x | 4.73x | 12.10x | 6.76x | 7.54x | 6.98x | 16.32x |
| Cash Conversion Cycle | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 22.01M | 127.73M | 114.72M | 131.45M | 103.52M | 78.81M | 30.83M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 30.83M |
| Capital Lease Obligations | 7.88M | 6.92M | 0 | 39.36M | 36.84M | 34.04M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 14.12M | 5K | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 47.86M | 168.65M | 155.41M | 186.99M | 149.46M | 116.97M | 52.51M |
| Total Debt | 8.54M | 7.88M | 1.5M | 41.13M | 38.92M | 36.49M | 33.57M |
| Net Debt | -14.35M | -20.5M | -141.24M | -18.84M | -27.46M | -33.04M | -78.71M |
| Debt / Equity | 1.08x | 0.20x | 0.00x | 0.16x | 0.15x | 0.18x | 0.10x |
| Debt / EBITDA | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | - | - | - |
| Total Equity | 7.91M▲ 0% | 38.6M▲ 388.3% | 344.75M▲ 793.1% | 249.48M▼ 27.6% | 253.11M▲ 1.5% | 199.52M▼ 21.2% | 346.18M▲ 73.5% |
| Equity Growth % | - | 388.3% | 793.13% | -27.63% | 1.46% | -21.17% | 73.51% |
| Book Value per Share | 0.09 | 0.44 | 5.55 | 2.84 | 2.68 | 1.83 | 2.98 |
| Total Shareholders' Equity | 7.91M | 38.6M | 344.75M | 249.48M | 253.11M | 199.52M | 346.18M |
| Common Stock | 13K | 40K | 88K | 88K | 102K | 108K | 136K |
| Retained Earnings | -51.13M | -103.1M | -161.34M | -269.51M | -371.26M | -501.56M | -603.15M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 10K | 17K | -765K | -3.71M | 186K | 336K | 224K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TNGX Cash Flow Statement
Tango Therapeutics, Inc. (TNGX) cash flow — operating, investing & free cash flow history
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -24.8M | 70.07M | -59.53M | -109.08M | -117.98M | -131.5M | -138.89M |
| Operating CF Margin % | -100.62% | 915.28% | -160.7% | -438.78% | -323% | -312.58% | -222.63% |
| Operating CF Growth % | - | 382.52% | -184.95% | -83.24% | -8.16% | -11.46% | -5.62% |
| Net Income | -14.1M | -51.97M | -58.23M | -108.18M | -101.74M | -130.3M | -101.59M |
| Depreciation & Amortization | 643K | 718K | 897K | 1.61M | 2.42M | 2.5M | 2.28M |
| Stock-Based Compensation | 1.69M | 1.76M | 7.83M | 14.23M | 19.08M | 28.9M | 26.43M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -14.74M | 890K | 1.32M | 1.75M | 234K | -849K | 1.2M |
| Working Capital Changes | 1.7M | 118.67M | -11.35M | -18.49M | -37.97M | -31.75M | -67.2M |
| Change in Receivables | 0 | -2M | 0 | 0 | 2M | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 1.17M | 1.23M | 1.1M | -1.71M | -1.18M | -825K |
| Cash from Investing | 848K | -145.47M | -183.43M | 26.4M | 41.43M | 86.13M | -40.87M |
| Capital Expenditures | -1.82M | -1.11M | -1.84M | -7.69M | -1.53M | -754K | -1.05M |
| CapEx % of Revenue | 7.37% | 14.45% | 4.96% | 30.94% | 4.18% | 1.79% | 1.68% |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 2.67M | -40K | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 11M | 80.88M | 357.32M | 1.61M | 82.41M | 47.66M | 222.5M |
| Debt Issued (Net) | 0 | 0 | 342.11M | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 0 | 1000K | 1000K | 0 | 1000K | 1000K | 1000K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 11M | 40K | -14.78M | 1.61M | 2.39M | 5.94M | -36K |
| Net Change in Cash | 25.17M▲ 0% | 5.49M▼ 78.2% | 114.36M▲ 1982.4% | -81.07M▼ 170.9% | 5.85M▲ 107.2% | 2.29M▼ 60.9% | 42.75M▲ 1767.6% |
| Free Cash Flow | -26.62M▲ 0% | 68.97M▲ 359.1% | -61.36M▼ 189.0% | -116.77M▼ 90.3% | -119.51M▼ 2.3% | -132.25M▼ 10.7% | -139.93M▼ 5.8% |
| FCF Margin % | -108% | 900.84% | -165.66% | -469.72% | -327.18% | -314.38% | -224.31% |
| FCF Growth % | - | 359.08% | -188.97% | -90.29% | -2.34% | -10.67% | -5.81% |
| FCF per Share | -0.30 | 0.79 | -0.99 | -1.33 | -1.26 | -1.21 | -1.20 |
| FCF Conversion (FCF/Net Income) | 1.76x | -1.35x | 1.02x | 1.01x | 1.16x | 1.01x | 1.37x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TNGX Key Ratios
Tango Therapeutics, Inc. (TNGX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -178.3% | -223.51% | -30.38% | -36.41% | -40.49% | -57.58% | -37.23% |
| Return on Invested Capital (ROIC) | - | -671.64% | -39.39% | -38.38% | -37.53% | -55.69% | -38.47% |
| Gross Margin | -30.93% | 78.77% | 100% | 100% | 100% | 100% | 96.34% |
| Net Margin | -57.18% | -678.84% | -157.21% | -435.14% | -278.54% | -309.73% | -162.85% |
| Debt / Equity | 1.08x | 0.20x | 0.00x | 0.16x | 0.15x | 0.18x | 0.10x |
| FCF Conversion | 1.76x | -1.35x | 1.02x | 1.01x | 1.16x | 1.01x | 1.37x |
| Revenue Growth | - | -68.94% | 383.83% | -32.89% | 46.93% | 15.17% | 48.29% |
TNGX SEC Filings & Documents
Tango Therapeutics, Inc. (TNGX) SEC filings — annual & quarterly reports (10-K, 10-Q)
TNGX Frequently Asked Questions
Tango Therapeutics, Inc. (TNGX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Tango Therapeutics, Inc. (TNGX) reported $62.4M in revenue for fiscal year 2025. This represents a 153% increase from $24.6M in 2019.
Tango Therapeutics, Inc. (TNGX) grew revenue by 48.3% over the past year. This is strong growth.
Tango Therapeutics, Inc. (TNGX) reported a net loss of $101.6M for fiscal year 2025.
Dividend & Returns
Tango Therapeutics, Inc. (TNGX) has a return on equity (ROE) of -37.2%. Negative ROE indicates the company is unprofitable.
Tango Therapeutics, Inc. (TNGX) had negative free cash flow of $139.9M in fiscal year 2025, likely due to heavy capital investments.
Explore More TNGX
Tango Therapeutics, Inc. (TNGX) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates